Mercer Global Advisors
WHWK

Mercer Global Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Mercer Global Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,100
Closed -$37K – 2166
2023
Q4 		$37K Buy
+18,100
New +$75.9K ﹤0.01% 1973

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mercer Global Advisors's WHWK Position: Q1 2024 in Review

Mercer Global Advisors sold out of Whitehawk Therapeutics (WHWK) in Q1 2024, closing a stake of 18,100 shares — an estimated $37K sold.

Mercer Global Advisors first reported a position in WHWK in Q4 2023 and held it in 1 quarter. The position peaked at $37K in Q4 2023. 60 funds tracked by Wall St. Rank hold WHWK as of Q1 2024.

  • Mercer Global Advisors reported no remaining Whitehawk Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Mercer Global Advisors sold 18,100 Whitehawk Therapeutics shares in Q1 2024, an estimated $37K.
  • Mercer Global Advisors first reported a position in Whitehawk Therapeutics in Q4 2023 and held it in 1 quarter.
  • Mercer Global Advisors's Whitehawk Therapeutics position peaked at $37K in Q4 2023.
  • 60 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2024.

Based on Mercer Global Advisors's 13F filing for Q1 2024, filed 15 May 2024.